Dublin, Aug. 16, 2021 (GLOBE NEWSWIRE) -- The "Diabetic Retinopathy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
The global diabetic retinopathy market reached a value of US$ 7.64 Billion in 2020. Looking forward, the publisher expects the market to grow at a CAGR of 5.6% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Diabetic retinopathy (DR) refers to the damage caused to the blood vessels in the retina by diabetes mellitus. This ailment is of two kinds, namely non-proliferative DR and proliferative or advanced DR. It is caused by fluctuations in the blood glucose levels resulting in an abnormal growth in the light-sensitive tissues present in the eye. The symptoms of DR include the visibility of dark spots or floating strings in the vision field, blurred or fluctuating vision, impaired color vision or loss of vision. It can be diagnosed through tests, such as fluorescein angiography and optical coherence tomography, and the treatment involves the use of intraocular steroid injection, laser treatment and vitrectomy.
The increasing prevalence of diabetes, along with the growing geriatric population across the globe, represent as the key factors driving the growth of the market. Furthermore, the rising incidence of blindness caused by DR is also providing a boost to the market growth. There is an increasing awareness among the masses regarding the available treatment alternatives and the benefits of early detection of DR. This has resulted in the widespread adoption of technologically advanced procedures and equipment, such as the improved ophthalmic diagnostic and surgical instruments. These procedures and equipment enable early detection and efficient treatment of the ailment with higher precision and minimal discomfort to the patient. Other factors, including the increasing healthcare expenditures, the implementation of favorable government policies to make advanced healthcare services available to the masses and extensive research and development (R&D) activities, are projected to drive the market further.
Breakup by Type:
- Proliferative Diabetic Retinopathy
- Non-proliferative Retinopathy
Breakup by Treatment Type:
- Anti VEGF Drugs
- Steroid Implants
- Laser Surgeries
- Vitrectomy
Breakup by End-User:
- Hospitals and Pharmacies
- Eye Clinics
- Ambulatory Surgical Centres (ASCs)
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Alimera Sciences, Allergan PLC, Ampio Pharmaceuticals, Bayer Healthcare, BCN Peptides, Genentech, Kowa Group, Novartis AG, Regeneron Pharmaceuticals Inc., Sirnaomics Inc., etc.
Key Questions Answered in This Report:
- How has the global diabetic retinopathy market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What has been the impact of COVID-19 on the global diabetic retinopathy market?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the end-user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global diabetic retinopathy market and who are the key players?
- What is the degree of competition in the industry?
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Diabetic Retinopathy Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Proliferative Diabetic Retinopathy
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Non-proliferative Retinopathy
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Treatment Type
7.1 Anti VEGF Drugs
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Steroid Implants
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Laser Surgeries
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Vitrectomy
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by End-User
8.1 Hospitals and Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Eye Clinics
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Ambulatory Surgical Centers (ASCs)
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
11 Value Chain Analysis
12 Porters Five Forces Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Alimera Sciences
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.2 Allergan Plc
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 Ampio Pharmaceuticals
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.4 Bayer Healthcare
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 BCN Peptides
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Financials
13.3.6 Genentech
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 SWOT Analysis
13.3.7 Kowa Group
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.8 Novartis AG
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.9 Regeneron Pharmaceuticals Inc.
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.9.4 SWOT Analysis
13.3.10 Sirnaomics Inc.
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
For more information about this report visit https://www.researchandmarkets.com/r/2d85w0
